Loading...
Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.
Wei, Feixue; Gaisa, Michael M; D'Souza, Gypsyamber; Xia, Ningshao; Giuliano, Anna R; Hawes, Stephen E; Gao, Lei; Cheng, Shu-Hsing; Donà, Maria Gabriella; Goldstone, Stephen E; Schim van der Loeff, Maarten F; Neukam, Karin; Meites, Elissa; Poynten, I Mary; Dai, Jianghong; Combes, Jean-Damien; Wieland, Ulrike; Burgos, Joaquin; Wilkin, Timothy J; Hernandez, Alexandra L; Iribarren Díaz, Mauricio; Hidalgo-Tenorio, Carmen; Valencia Arredondo, Marleny; Nyitray, Alan G; Wentzensen, Nicolas; Chow, Eric Pf; Smelov, Vitaly; Nowak, Rebecca G; Phanuphak, Nittaya; Woo, Yin Ling; Choi, Yoojin; Hu, Yifei; Schofield, Alice M; Woestenberg, Petra J; Chikandiwa, Admire T; Hickey, Andrew C; de Pokomandy, Alexandra; Murenzi, Gad; Péré, Hélène; Del Pino, Marta; Ortiz, Ana P; Charnot-Katsikas, Angella; Liu, Xing; Chariyalertsak, Suwat; Strong, Carol; Ong, Jason J; Yunihastuti, Evy; Etienney, Isabelle; Ferré, Valentine M; Zou, Huachun; Segondy, Michel; Chinyowa, Simbarashe; Alberts, Catharina J; Clifford, Gary M
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date
2021-07-30
Research Projects
Organizational Units
Journal Issue
Title
Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.
Translated Title
Published in
Lancet HIV 2021; 8(9):e531-43
Abstract
The systematic review identified 93 eligible studies, of which 64 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1·8% (91 of 5190) and HR-HPV prevalence was 6·9% (345 of 5003); among HIV-positive MSW the prevalences were 8·7% (59 of 682) and 26·9% (179 of 666); among HIV-negative MSM they were 13·7% (1455 of 10 617) and 41·2% (3798 of 9215), and among HIV-positive MSM 28·5% (3819 of 13 411) and 74·3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5·6% (two of 36) among those age 15-18 years and 28·8% (141 of 490) among those age 23-24 years (ptrend=0·0091); prevalence was 31·7% (1057 of 3337) among those age 25-34 years and 22·8% (451 of 1979) among those age 55 and older (ptrend<0·0001). HPV16 prevalence in HIV-negative MSM was 6·7% (15 of 223) among those age 15-18 and 13·9% (166 of 1192) among those age 23-24 years (ptrend=0·0076); the prevalence plateaued thereafter (ptrend=0·72). Similar age-specific patterns were observed for HR-HPV. No significant differences for HPV16 or HR-HPV were found by age for either HIV-positive or HIV-negative MSW. HSIL+ detection ranged from 7·5% (12 of 160) to 54·5% (61 of 112) in HIV-positive MSM; after adjustment for heterogeneity, HIV was a significant predictor of HSIL+ (aPR 1·54, 95% CI 1·36-1·73), HPV16-positive HSIL+ (1·66, 1·36-2·03), and HSIL+ in HPV16-positive MSM (1·19, 1·04-1·37). Among HPV16-positive MSM, HSIL+ prevalence increased with age.